Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans  by Freedman, Barry I. et al.
Polymorphisms in the non-muscle myosin heavy
chain 9 gene (MYH9) are strongly associated with
end-stage renal disease historically attributed to
hypertension in African Americans
Barry I. Freedman1, Pamela J. Hicks2, Meredith A. Bostrom2, Mary E. Cunningham3, Yongmei Liu3,
Jasmin Divers3, Jeffrey B. Kopp4, Cheryl A. Winkler5, George W. Nelson5, Carl D. Langefeld3
and Donald W. Bowden1,2,6
1Internal Medicine/Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; 2Biochemistry, Wake
Forest University School of Medicine, Winston-Salem, North Carolina, USA; 3Biostatistical Sciences, Wake Forest University School of
Medicine, Winston-Salem, North Carolina, USA; 4Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, Maryland, USA; 5SAIC National Cancer Institute-Frederick, Frederick, Maryland, USA and 6Center for Human
Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
African Americans have high incidence rates of end-stage renal
disease (ESRD) labeled as due to hypertension. As recent studies
showed strong association with idiopathic and HIV-related focal
segmental glomerulosclerosis and non-muscle myosin heavy
chain 9 (MYH9) gene polymorphisms in this ethnic group, we
tested for MYH9 associations in a variety of kidney diseases.
Fifteen MYH9 single-nucleotide polymorphisms were evaluated
in 175 African Americans with chronic glomerulonephritis-
associated ESRD, 696 African Americans reportedly with
hypertension-associated ESRD, and 948 control subjects
without kidney disease. Significant associations were detected
with 14 of the 15 polymorphisms in all 871 non-diabetic
patients with ESRD. In hypertension-associated ESRD cases
alone, significant associations were found with 13 MYH9
polymorphisms and the previously reported E1 haplotype.
Thus, hypertension-associated ESRD in African Americans is
substantially related to MYH9 gene polymorphisms and this
may explain the poor response to blood pressure control in
those diagnosed with hypertensive nephrosclerosis. It is
possible that many African Americans classified as having
hypertension-associated ESRD have occult MYH9-associated
segmental or global glomerulosclerosis. Our study shows that
gene-environment and/or gene–gene interactions may initiate
kidney disease in genetically susceptible individuals, because
African Americans homozygous for MYH9 risk alleles do not
universally develop kidney disease.
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Hypertensive nephrosclerosis and chronic glomerular
diseases were reported as the cause of end-stage renal disease
(ESRD) in 35% of incident dialysis patients in 2005.1 Both
syndromes are reported more often in African Americans
than European Americans, an effect likely due to biologic
differences and physician bias.2,3 A causative link between
hypertension and nephrosclerosis has not been clearly
established.4 Although epidemiologic reports consistently
demonstrate graded relationships between serum creatinine
concentration and elevated blood pressure, this could be the
result of secondary hypertension in the setting of a primary
renal disease.5 In spite of renal biopsy studies revealing
segmental and global forms of glomerulosclerosis (and other
primary glomerular diseases) in those with clinically
diagnosed hypertensive nephrosclerosis,6 along with the lack
of correlation between systemic blood pressure and renal
microvascular changes,7,8 the failure of aggressive blood
pressure lowering, even with the use of angiotensin-convert-
ing enzyme inhibitors to slow nephropathy progression in
hypertensive African Americans with non-diabetic chronic
kidney disease,9,10 clinicians commonly diagnose mild-to-
moderate essential hypertension as a cause of nephropathy.
Kopp et al.11 demonstrated that the non-muscle myosin
heavy chain 9 (MYH9) gene was associated with biopsy-proven
focal segmental glomerulosclerosis (FSGS) and HIV-associated
nephropathy (HIVAN) in African Americans, using mapping
by admixture linkage disequilibrium, an approach suited to
diseases with marked ethnic differences in risk.12 The
attributable risk due to MYH9 was 70% in FSGS and 100%
in HIVAN, with odds ratios (OR) in the 4–5 range.11 MYH9
was associated with FSGS in European Americans, but the
attributable risk was smaller due to the low frequency of the
MYH9 risk haplotype in European Americans (4% compared
with 60% of African Americans). Association between MYH9
was also observed in an extension cohort of 241 African
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Americans with clinically diagnosed hypertension-associated
ESRD (H-ESRD) from North Carolina (OR 1.8, P¼ 0.003).11
Kao et al.13 replicated these findings by detecting association
between MYH9 and several non-diabetic etiologies of ESRD
among African Americans in the MALD arm of the ‘Family
Investigation of Nephropathy and Diabetes’ (FIND). They
estimated that replacing the African American MYH9 risk
alleles with European American variants would reduce non-
diabetic ESRD by 70% in the African American population.
Association was detected separately in FIND cases with FSGS
and HIVAN, with weaker association in 347 individuals with
H-ESRD.13
The current report evaluates the largest number of
unrelated African Americans with H-ESRD to date for
association with the MYH9 gene, for the purpose of
providing enhanced power to detect additional genomic
regions associated with disease. All subjects were born in the
southeastern United States of America, where African
Americans are diagnosed with H-ESRD 20 times more often
than European Americans, the greatest ethnic disparity for
this renal disease reported in the nation.
RESULTS
DNA from 871 non-diabetic ESRD cases and 948 unrelated
non-renal disease controls were genotyped for 15 MYH9 gene
single-nucleotide polymorphisms (SNPs) previously shown
to be significantly associated with FSGS and HIVAN.11 On
the basis of medical record review, the ESRD case group was
classified as containing 696 individuals clinically diagnosed
with H-ESRD, 80 with presumed chronic glomerular disease,
15 renal biopsy-proven FSGS, 20 HIVAN, 25 lupus nephritis,
and 35 other non-diabetic etiologies of kidney disease. Of the
696 H-ESRD cases, DNA from 262 cases was previously sent
to Dr Jeffrey Kopp (NIDDK), and 241 of these samples were
included in a prior publication.11 These 262 individuals were
retained in our overall analysis to enhance power to detect
new polymorphisms independent of the previously reported
risk haplotype, and the 434 ‘new’ H-ESRD cases (not
previously genotyped) were evaluated separately for replica-
tion. Table 1 contains demographic characteristics in study
participants. Cases initiated dialysis therapy at nearly 49 years
of age, typical of the African-American non-diabetic
population in the United States.1 Among the 948 non-renal
disease controls, 558 (58.9%) were asked whether they had
high blood pressure, and 34% of them (192/558) reported
having hypertension, with mean age at onset 44.0±13.0 years
(median 45 years). Frequentist estimation of individual
ancestry proportion (FRAPPE) was used to calculate the
proportion of African ancestry in cases and controls.14 The
70 ancestry informative markers revealed mean African
ancestry proportions of 0.79 (s.d.¼ 0.10) in controls and
0.81 (s.d.¼ 0.10) in non-diabetic ESRD cases.
The 15 SNPs genotyped spanned 49.3 kb of MYH9,
encompassing the majority of the coding region (Figure 1).
Genotyping success rates for the MYH9 SNPs were
96.2–98.74% in cases and controls. A concordance rate of
99.8% was observed in 465 duplicate samples that were
genotyped for quality control purposes. Ancestry informative
marker SNPs genotyped at a rate of 93.1–98.5%. Table 2a
summarizes allele frequencies and results of the single SNP
genotypic association analysis for the non-diabetic ESRD cases
and controls. Table 2b contains single SNP genotypic
association results for the 696 cases with H-ESRD (excluding
the 175 cases with chronic glomerular disease). SNP rs2187776
failed to meet Hardy–Weinberg equilibrium in the control
population (P¼ 0.0005) and was removed from further
analysis. The initial age, gender, and admixture-adjusted
analysis revealed single SNP associations with non-diabetic
ESRD, most significantly in the recessive model, with 13 of the
14 SNPs analyzed. These associations were comparably
significant without adjustment for admixture (Tables 2a and b).
Tables 3a and b contain results of a priori MYH9 E1
haplotype associations in all 871 non-diabetic ESRD cases, as
well as limited to the 696 cases with H-ESRD, respectively.
This analysis was performed to allow for comparison with
results previously reported by Kopp et al.11 in FSGS and
HIVAN and to allow for the identification of novel risk loci
after adjusting for the published risk haplotype. The age,
gender, and ancestry adjusted P-value for the E1 risk
haplotype determined using a weighted logistic regression
analysis in all non-diabetic cases of ESRD vs controls was
1.22 1015, with 71.8% of cases and 57.3% of controls
homozygous for the risk haplotype (OR 2.38). Limited to the
696 H-ESRD cases, the ancestry-adjusted E1 haplotype P-
value was 4.52 1012 (OR 2.23); a result that survives
stringent Bonferroni correction. A novel association in a
second haplotype block L1, (1324) consisting of rs7078,
rs12107, rs735853, and 5756129, is also displayed.
Table 1 | Demographic characteristics of African American non-diabetic ESRD cases and controls
Non-diabetic ESRD cases (N¼ 871) Non-nephropathy controls (N¼ 948) P-value
Sex, % female 44 57 o0.0001
Age at recruitment (years) 54.2 (53)±14.5 49.6 (49)±11.6 o0.0001
Age at ESRD diagnosis (years) 48.7 (48)±15.5 NA —
Age at HTN diagnosis (years) 34.9 (34)±13.2 44.0 (45)±13.0a o0.0001
BMI at recruitment (kg/m2) 26.9 (25.5)±7.1 29.8 (28.9)±7.0 o0.0001
Duration of ESRD (years) 5.5 (4)±5.9 NA —
Duration of HTN (years) 18.7 (16)±13.3 Not collected —
ESRD, end-stage renal disease; HTN, hypertension; NA, not appliacble.
aSubset of 192 controls reporting a diagnosis of hypertension (of 558 questioned). Data presented as mean (median)±s.d.
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Tables 4a and b contain the results of single SNP and
haplotype association analyses limited to the 434 newly
genotyped cases with H-ESRD not analyzed in the earlier
report.11 Despite reduced power in the smaller but
independent sample, single SNP associations remained highly
significant (P-values ranged 0.05–9.1 1011 recessive;
admixture adjusted OR 1.35–3.23), and the 3224 and 1324
haplotypes were also strongly associated (P¼ 2.6 106 and
3.1 107, respectively). This analysis replicated the associa-
tion between MYH9 and H-ESRD in a new sample.
Tables 5a and b contains SNP association analyses,
adjusted for the presence of the powerful E1 risk haplotype
(Table 5a—E1 additive model, 5b—E1 recessive model).
After adjustment for the E1 haplotype, rs5756152, rs12107,
rs1005570, rs16996674, and rs16996677 remained indepen-
dently associated with non-diabetic forms of ESRD
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Figure 1 | Gene structure and linkage disequilibrium plot of 49 kb of the MYH9 gene. The genotyped single-nucleotide polymorphisms
(SNPs) are shown in relation to their position in the gene. InterSNP D0 values are shown on the plot.
Table 2a | MYH9 single SNP associations in 871 African Americans with non-diabetic ESRDa
Unadjusted for admixture After admixture adjustment
Risk allele frequencies HWE Recessive test Recessive test
Marker Risk allele Cases Controls Cases Controls OR P-value OR P-value
rs7078 A 0.897 0.849 0.352 0.192 1.55 0.0004 1.50 0.0110
rs12107 G 0.927 0.890 1 0.347 1.77 3.43E05 1.76 4.57E05
rs735853 C 0.938 0.891 0.553 0.005 1.90 1.23E05 1.78 0.0001
rs5756129 T 0.853 0.788 0.017 0.147 1.68 4.37E06 1.66 8.29E06
rs5756130 C 0.907 0.874 0.147 0.865 1.52 0.0014 1.54 0.0110
rs4821480 G 0.755 0.607 0.000 0.101 2.59 1.01E18 2.47 8.48E17
rs2032487 C 0.760 0.619 0.000 0.114 2.47 3.19E17 2.36 1.98E15
rs4821481 C 0.753 0.607 0.000 0.118 2.55 2.82E18 2.44 2.28E16
rs3752462 T 0.821 0.733 0.291 0.251 1.91 2.68E09 1.84 2.79E08
rs5756152 A 0.381 0.253 0.023 1 3.32 7.37E11 3.40 5.84E11
rs1557539 G 0.982 0.978 1 1 1.31 0.3048 1.36 0.2491
rs1005570 A 0.557 0.444 0.069 0.762 2.17 3.61E10 2.16 5.86E10
rs16996674 T 0.340 0.236 0.124 0.918 2.80 2.54E07 2.84 2.37E07
rs16996677 A 0.361 0.271 0.257 0.778 2.26 6.91E06 2.27 7.68E06
ESRD, end-stage renal disease; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for age, gender.
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(P¼ 0.047–7.1 106; OR 1.20–1.50, additive). This suggests
that although E1 by itself explained a significant portion of
the variation, additional SNPs in the region independently
contribute to the risk of non-diabetic ESRD.
Table 6 contains the results of the multilocus SNP analysis
using logistic regression. After adjustment for age, gender,
and admixture, three SNPs exhibited independent evidence
for association, rs4821480, rs5756152, and rs12107. The
estimated OR for an individual SNP in this analysis adjusts
for all effects in the model, including all other loci. In
addition, only rs4821480 was part of the E1 risk haplotype,
associated at a P-value of 7.0 109. This model demon-
strates that after controlling for age, gender, and admixture
three SNPs provide discriminating power to distinguish
between non-diabetic ESRD cases and non-nephropathy
controls.
We examined the contribution of the covariates and SNPs
to the C-statistic (area under the receiver–operator char-
acteristic curve).15 The C-statistic is a nonparametric
measure of the predictive ability of a model and a function
of sensitivity and specificity. It is the probability that for a
randomly selected pair of subjects, one with non-diabetic
ESRD and one without, the individual with ESRD has a
higher predicted probability of disease than the individual
without ESRD. A C¼ 0.50 is completely random. Using the
same sample for all three estimates, the C-statistic was
C¼ 0.63 for the model with age and gender only, C¼ 0.64 for
age, gender and admixture estimate, and 0.70 for age, gender,
admixture, and the three SNPs. Thus, the three SNPs
markedly increase the predictive ability of the model in
these data, as well as are individually statistically significant.
The individual SNP association analysis and stepwise
association analysis (Tables 2a, 2b and 6) identified multiple
SNPs outside of the original E1 haplotype that predicted
risk for non-diabetic ESRD. In particular, the first four SNPs
in Figure 1, rs7078, rs12107, rs735853, and rs5756129,
Table 2b | MYH9 single SNP associations in 696 African Americans with H-ESRDa
Unadjusted for admixture After admixture adjustment
Risk allele frequencies HWE Recessive test Recessive test
Marker Risk Allele Cases Controls Cases Controls OR P-value OR P-value
rs7078 A 0.898 0.849 0.529 0.192 1.56 8.16E04 1.51 0.0020
rs12107 G 0.923 0.890 1 0.347 1.7 2.96E04 1.69 4.24E04
rs735853 C 0.933 0.891 0.528 0.005 1.79 1.79E04 1.67 0.0010
rs5756129 T 0.856 0.788 0.028 0.147 1.74 5.56E06 1.72 9.41E06
rs5756130 C 0.913 0.874 0.083 0.865 1.69 2.17E04 1.71 1.86E04
rs4821480 G 0.751 0.607 0.0001 0.101 2.48 2.00E15 2.37 8.66E14
rs2032487 C 0.754 0.619 0.0003 0.114 2.36 5.73E14 2.25 2.27E12
rs4821481 C 0.747 0.607 0.0001 0.118 2.43 6.88E15 2.32 2.88E13
rs3752462 T 0.819 0.733 0.438 0.251 1.92 2.49E08 1.84 2.46E07
rs5756152 A 0.380 0.253 0.0600 1 3.42 2.00E10 3.47 2.00E10
rs1557539 G 0.982 0.978 1 1 1.25 0.4299 1.29 0.3768
rs1005570 A 0.558 0.444 0.641 0.763 2.07 2.81E08 2.07 3.74E08
rs16996674 T 0.337 0.236 0.170 0.918 2.83 6.77E07 2.86 6.99E07
rs16996677 A 0.362 0.271 0.402 0.778 2.31 1.17E05 2.33 1.18E05
H-ESRD, hypertension-associated end-stage renal disease; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for age, gender.
Table 3a | Logistic regression results—MYH9 haplotypes (all 871 non-diabetic ESRD cases)a
Haplotype frequency No admixture adjustment Admixture adjustment
Haplotype Model Case Control P-value OR 95% CI P-value OR 95% CI
E1 haplotype consisting of SNPs: rs4821480, rs2032487, rs4821481, and rs3752462
3224 Dominant 0.7181 0.5728 1.04E06 2.06 (1.54, 2.76) 9.09E06 1.94 (1.45, 2.60)
Additive 1.11E16 1.87 (1.61, 2.17) 7.55E15 1.814 (1.56, 2.11)
Recessive 3.462E17 2.48 (2.01, 3.06) 1.22E15 2.38 (1.93, 2.95)
4442 Dominant 0.1455 0.2291 1.35E09 0.51 (0.41, 0.63) 2.05E08 0.53 (0.43, 0.66)
Additive 4.74E10 0.56 (0.46, 0.67) 1.04E08 0.58 (0.48, 0.70)
Recessive 0.000595 0.40 (0.24, 0.68) 0.002573 0.45 (0.26, 0.75)
4444 Dominant 0.0977 0.1589 1.20E06 0.55 (0.43, 0.70) 3.65E06 0.56 (0.44, 0.72)
Additive 4.88E06 0.60 (0.48, 0.75) 1.34E05 0.62 (0.49, 0.77)
Recessive 0.3175 0.68 (0.33, 1.44) 0.35212 0.70 (0.33, 1.48)
L1 haplotype consisting of SNPs: rs7078, rs12107, rs735853, and rs5756129
1324 Dominant 0.7217 0.5746 3.91E09 2.49 (1.84, 3.37) 6.15E08 2.33 (1.72, 3.17)
Additive 1.11E16 1.90 (1.64, 2.21) 3.22E15 1.85 (1.59, 2.15)
Recessive 8.10E15 2.29 (1.86, 2.83) 1.66E13 2.21 (1.79, 2.73)
CI, confidence interval; ESRD, end-stage renal disease; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for age, gender.
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potentially explain additional risk and comprise a second
haplotype block. The 1324 L1 haplotype in this block was
present in 72.2% of ESRD cases and 57.5% of controls. A
logistic regression model that adjusted for the original E1
(3224) haplotype under a recessive model, as well as for age,
gender, and admixture, provides evidence that the second
haplotype (1324) explained independent risk for non-
diabetic ESRD (P¼ 0.00009, additive) (Table 7). Collectively,
Table 3b | Logistic regression results—MYH9 haplotypes (696 hypertension-associated ESRD cases)a
No admixture adjustment Admixture adjustment
Haplotype Model P-value OR 95% CI P-value OR 95% CI
E1 haplotype consists of SNPs: rs4821480, rs2032487, rs4821481, and rs3752462
3224 Dominant 4.73E06 2.08 (1.52, 2.86) 3.576E05 1.95 (1.42, 2.68)
Additive 1.49E13 1.83 (1.56, 2.15) 5.46E12 1.77 (1.50, 2.08)
Recessive 2.01E13 2.32 (1.86, 2.91) 4.52E12 2.23 (1.78, 2.80)
4442 Dominant 4.72E09 0.49 (0.39, 0.63) 7.56E08 0.52 (0.41, 0.66)
Additive 1.70E09 0.54 (0.44, 0.66) 3.85E08 0.57 (0.46, 0.69)
Recessive 0.0008965 0.38 (0.21, 0.67) 0.003923 0.42 (0.24, 0.76)
4444 Dominant 0.0002161 0.62 (0.48, 0.80) 0.000415 0.63 (0.49, 0.81)
Additive 0.0002957 0.65 (0.52, 0.82) 0.000541 0.66 (0.52, 0.84)
Recessive 0.2595042 0.61 (0.26, 1.44) 0.274605 0.62 (0.26, 1.46)
Second haplotype consists of SNPs: rs7078, rs12107, rs735853, and rs5756129
1324 Dominant 1.40E07 2.41 (1.74, 3.33) 1.73E06 2.24 (1.61, 3.11)
Additive 1.95E14 1.88 (1.60, 2.21) 7.90E13 1.82 (1.54, 2.14)
Recessive 6.15E13 2.27 (1.82, 2.84) 1.09E11 2.19 (1.74, 2.74)
CI, confidence interval; ESRD, end-stage renal disease; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for age, gender.
Table 4a | MYH9 SNP associations in 434 new H-ESRD cases (excluding subjects evaluated in the study by Kopp et al.11)
Unadjusted for admixture After admixture adjustment
Risk allele frequencies HWE Recessive testa Recessive testa
Marker Risk allele Cases Controls Cases Controls OR P-value OR P-value
rs7078 A 0.892 0.849 0.452 0.192 1.39 0.0293 1.35 0.0516
rs12107 G 0.919 0.890 1 0.347 1.62 0.0043 1.59 0.0066
rs735853 C 0.943 0.891 0.635 0.005 2.21 3.39E05 2.01 3.02E04
rs5756129 T 0.851 0.788 0.053 0.147 1.62 5.60E04 1.60 8.53E04
rs5756130 C 0.902 0.874 0.162 0.865 1.43 0.0260 1.44 0.0235
rs4821480 G 0.752 0.607 0.0007 0.101 2.52 1.91E12 2.36 9.13E11
rs2032487 C 0.755 0.619 0.0007 0.114 2.39 2.61E11 2.24 1.20E09
rs4821481 C 0.752 0.607 0.0007 0.118 2.51 2.20E12 2.35 1.00E10
rs3752462 T 0.810 0.733 0.085 0.251 1.81 8.10E06 1.72 6.21E05
rs5756152 A 0.382 0.253 0.261 1 3.21 4.75E08 3.23 7.17E08
rs1557539 G 0.983 0.978 1 1 1.22 0.5534 1.27 0.4718
rs1005570 A 0.547 0.444 0.846 0.763 1.86 2.91E05 1.84 4.89E05
rs16996674 T 0.333 0.236 0.914 0.918 2.30 4.08E04 2.33 4.09E04
rs16996677 A 0.363 0.271 0.917 0.778 2.05 8.56E04 2.06 9.06E04
H-ESRD, hypertension-associated end-stage renal disease; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; SNP, single-nucleotide polymorphism.
E1 haplotype consisting of SNPs: rs4821480, rs2032487, rs4821481, and rs3752462.
aAge and gender adjusted.
Table 4b | MYH9 haplotype associations in 434 new H-ESRD cases (excluding subjects evaluated in the study by Kopp et al.11)
Haplotype frequency
Haplotype
Haplotype Case Control P-value
E1 Haplotype consists of SNPs: rs4821480, rs2032487, rs4821481, rs3752462
3224 0.7058 0.5728 2.64E06
4442 0.1446 0.2291 4.77E03
4444 0.1018 0.1589 3.05E04
Second Haplotype consists of SNPs: rs7078, rs12107, rs735853, rs5756129
1324 0.7190 0.5744 3.09E07
1334 0.0475 0.1035 5.90E04
H-ESRD, hypertension-associated end-stage renal disease; SNP, single-nucleotide polymorphism.
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it is clear from the individual SNP analysis, the multiple locus
analysis, and the multiple haplotype analysis that there were
several loci with independent evidence for association to
non-diabetic ESRD. The relatively high linkage disequili-
brium (LD) within the region complicates the elucidation of
these effects. However, these multilocus analyses test for
associations conditional on the effects at the genotyped loci
that are in LD. Finally, rs5756152 remained an independent
predictor of risk, even after adjusting for the 1324 and 3224
risk haplotypes (data not shown).
DISCUSSION
The present analyses demonstrate that MYH9 gene poly-
morphisms are associated with non-diabetic etiologies of
ESRD in African Americans, particularly with kidney failure
that had historically been attributed to essential hyperten-
sion. This gene exhibits impressive evidence for association
with common, complex kidney diseases, with ORs as high as
3.4 for associated SNPs. This is the largest report containing
cases with H-ESRD, and all participants were born in the
southeastern United States of America, the region having the
highest ESRD incidence rates and the greatest African
American/European American disparity in non-diabetic
ESRD. We extend the results of earlier reports by replicating
association in 434 newly genotyped cases with H-ESRD and
by demonstrating independent contributions of MYH9 SNPs
and haplotypes in patients with non-diabetic ESRD, beyond
the previously described E1 haplotype (although it is
conceivable that a causal SNP could be in LD with multiple
regions in the gene).11,13 Our findings remain significant after
adjusting for age, gender, and multiple testing, factors not
previously addressed. The strong MYH9 association observed
in these individuals, as well as those in the FSGS cohorts
recruited throughout the United States and the FIND sample,
mirrors the familial aggregation of non-diabetic forms of
ESRD observed in African Americans in the southeastern
United States of America, Los Angeles, Cleveland, and
Alabama.16 It is clear that MYH9 is a gene with substantial
impact on common forms of non-diabetic ESRD in the
African-American population.
Table 5a | Logistic regression results for individual SNPs,
adjusting for 3224 haplotype (additive model) in all 871
casesa
No admixture adjustment Admixture adjustment
SNP P-value OR 95% CI P-value OR 95% CI
rs7078 0.887 1.02 (0.79, 1.31) 0.9309 1.01 (0.79, 1.30)
rs12107 0.0079 1.43 (1.10, 1.87) 0.0078 1.44 (1.10, 1.88)
rs735853 0.0992 1.27 (0.96, 1.68) 0.1629 1.22 (0.92, 1.63)
rs5756129 0.4995 0.92 (0.73, 1.17) 0.6384 0.95 (0.75, 1.20)
rs5756130 0.187 0.84 (0.64, 1.09) 0.3258 0.87 (0.67, 1.14)
rs5756152 1.16E05 1.49 (1.25, 1.77) 7.15E06 1.50 (1.26, 1.80)
rs1557539 0.4082 1.26 (0.73, 2.15) 0.354 1.29 (0.75, 2.21)
rs1005570 0.0163 1.24 (1.04, 1.47) 0.0131 1.25 (1.05, 1.48)
rs16996674 0.001 1.35 (1.13, 1.61) 0.0009 1.35 (1.13, 1.62)
rs16996677 0.0454 1.20 (1.00, 1.43) 0.0469 1.20 (1.00, 1.43)
CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for age, gender.
Table 5b | Logistic regression results for individual SNPs,
adjusting for 3224 haplotype (recessive model) in all 871
casesa
No admixture adjustment Admixture adjustment
SNP P-value OR 95% CI P-value OR 95% CI
rs7078 0.9362 1.01 (0.78, 1.32) 0.99 1.00 (0.77, 1.31)
rs12107 0.0051 1.49 (1.13, 1.97) 0.0049 1.50 (1.13, 1.98)
rs735853 0.0808 1.31 (0.97, 1.78) 0.1455 1.26 (0.92, 1.71)
rs5756129 0.9439 0.99 (0.76, 1.29) 0.9469 1.01 (0.77, 1.32)
rs5756130 0.682 0.94 (0.71, 1.25) 0.8735 0.98 (0.74, 1.30)
rs5756152 7.17E05 2.18 (1.48, 3.20) 3.07E05 2.29 (1.55, 3.37)
rs1557539 0.5483 1.18 (0.69, 2.03) 0.4756 1.22 (0.71, 2.09)
rs1005570 0.0133 1.42 (1.08, 1.87) 0.0086 1.45 (1.10, 1.91)
rs16996674 0.0035 1.84 (1.22, 2.76) 0.0022 1.90 (1.26, 2.87)
rs16996677 0.0415 1.48 (1.02, 2.15) 0.0303 1.52 (1.04, 2.22)
CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for age, gender.
Table 6 | Results of stepwise logistic regression analysis performed on all SNPs
Variable Genetic model Risk allele
Risk allele
frequency case
Risk allele
frequency control P-value OR 95% CI
Agea 3.45E14 1.17 (1.12, 1.22)
Gender 3.34E07 0.57 (0.46, 0.71)
Admixa 0.0011 1.54 (1.19, 2.00)
rs4821480 Recessive G 0.76 0.61 6.98E09 1.99 (1.58, 2.51)
rs5756152 Additive A 0.38 0.25 2.92E05 1.45 (1.22, 1.73)
rs12107 Recessive G 0.93 0.89 0.01 1.46 (1.10, 1.95)
CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
aOdds ratio and 95% CI for age and admixture proportion of 5 years and 0.25, respectively.
Table 7 | Results of logistic regression analysis using both
associated haplotypes
Variable Genetic model P-value OR 95% CI
Agea 7.34E14 1.17 (1.12, 1.22)
Gender 1.89E07 1.03 (1.02, 1.04)
Admixa 0.0059 1.43 (1.11, 1.84)
3224b Recessive 4.79E05 1.73 (1.33, 2.26)
1324c Additive 9.07E05 1.46 (1.21, 1.76)
CI, confidence interval; OR, odds ratio.
aOdds ratio and 95% CI for age and admixture proportion of 5 years and 0.25,
respectively.
b3224 refers to the E1 risk haplotype (rs4821480, rs2032487, rs4821481, and
rs3752462).
c1324 refers to the L1 risk haplotype (rs7078, rs12107, rs735853, and rs5756129).
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As all MYH9 risk homozygotes do not develop kidney
disease, environmental exposures and/or interactions with
other genes are clearly necessary to initiate MYH9-associated
nephropathy in genetically susceptible hosts. Although it
remains possible that high blood pressure is one such
initiating factor, this remains to be proven. HIV infection
appears to be a common initiator of renal disease in African
Americans and serves as an example of one environmental
exposure that can initiate MYH9-associated HIVAN. Other
non-HIV viral factors, as well as toxin exposures, may also be
initiators of kidney disease in MYH9 risk homozygotes. These
important gene–environment and gene–gene interactions
require further evaluation.
The recent demonstration that MYH9 gene polymorph-
isms commonly cause idiopathic and HIV-associated FSGS in
the African-American population makes this gene the most
common inherited cause of FSGS, far more frequent than
polymorphisms in the ACTN4 (a-actinin 4) and TRPC6
(transient receptor potential cation channel 6) genes, or
glomerulosclerosis due to NPHS2 (podocin), CD2AP (CD2-
associated protein), WT1 (Wilm’s tumor-1) genes, and mt
DNA tRNA leucine.17–21 The MYH9 gene product, myosin-
IIA, is a mechanoenzyme localized to the podocyte foot
process and is responsible for moving actin filaments in cells.
The proteins comprising the filtration slit barrier actively
regulate actin dynamics to maintain normal cell structure.
Mutations affecting other podocyte proteins rearrange the
actin cytoskeleton, ultimately disrupting the filtration barrier
and causing renal disease. We hypothesize that polymorph-
isms in the MYH9 gene may directly cause podocyte injury
resulting in either FSGS or global glomerulosclerosis in the
absence of hypertension, although this remains to be proven.
The observed ethnic disparities in H-ESRD, FSGS, and
HIVAN, all far more common in African Americans, may
also be due in part to the lower frequency of MYH9 risk
alleles in European Americans, who demonstrate a 4%
frequency of the E1 risk haplotype.11,13 This suggests that
MYH9, in addition to environmental factors and socio-
economic status, contributes to ethnic disparities in non-
diabetic forms of ESRD.
This disease association may alter our understanding of
the factors that ‘initiate’ H-ESRD. Several studies revealed
that high blood pressure does not commonly lead to
progressive nephropathy in African-American patients.22,23
The few hypertensive African Americans who demonstrate
progressive kidney disease are typically labeled as having
‘hypertensive nephrosclerosis,’ which is presumed to progress
to H-ESRD. It is possible that individuals harboring MYH9
risk alleles may be more likely to develop renal failure due to
a primary renal disease process, although the role of high
blood pressure requires further study. The frequency of the
MYH9 E1 risk haplotype was similar in hypertensive African
Americans from HyperGEN and in the general community.24
This result may lessen the likelihood that high blood pressure
per se is a proximate cause of MYH9-associated nephropathy.
We further hypothesize that the MYH9 association with
H-ESRD could explain the failure of intensive blood pressure
reduction, including with the use of ACE inhibition, to slow
nephropathy progression in hypertensive African Americans
with chronic kidney disease.9,10,25 Prior to these reports,
MYH9 was associated with rare autosomal dominant forms
of macrothrombocytopenia, often with variable degrees of
sensorineural deafness, cataracts, neutrophil inclusions, and
glomerular disease.26
African American patients clinically labeled with ‘hyper-
tensive nephrosclerosis’ and with non-nephrotic proteinuria
have been shown to have FSGS on renal biopsy.6 In contrast,
renal biopsies from a small subset of African American Study
of Kidney Disease and Hypertension (AASK) participants
were interpreted as being ‘consistent with hypertension-
associated kidney disease.’ Renal arteriolar changes that were
historically ascribed to high blood pressure did not correlate
with measured blood pressure in AASK participants.7 The
majority of subjects in AASK with renal biopsies had global
glomerulosclerosis with interstitial fibrosis. It is possible that
global glomerulosclerosis could result from polymorphisms
in MYH9, and be part of a disease spectrum linking FSGS
with global glomerulosclerosis. We propose that DNA
samples from AASK participants be tested for association
with MHY9 to address this intriguing possibility.
African Americans with nonspecific and incompletely
characterized causes of ESRD, typically attributed to
hypertension and chronic glomerular diseases, were thought
to be a heterogeneous group consisting of several different
diseases.4,27,28 The MYH9 association with H-ESRD in these
696 patients (262 previously sent to the Laboratory of
Genomic Diversity at the National Cancer Institute and 434
newly genotyped cases), coupled with the results in 347 FIND
participants with H-ESRD from Maryland reveal a unifying
major genetic etiology for this syndrome. Although African
Americans develop ESRD attributed to diabetes mellitus four
times more often than European Americans, MYH9 associa-
tions have not yet been observed in African Americans with
type 2 diabetes-associated ESRD, suggesting that this gene
relates to non-diabetic forms of nephropathy.11,13 One
limitation of our report is the potential for recruitment bias;
however, similar results seen in the FIND appear to make this
less likely. In addition, individuals classified as having
H-ESRD in the absence of quantified proteinuria may
actually have had proteinuria and underlying FSGS. This
difficulty plagues all existing genetic and epidemiologic
analyses involving H-ESRD. Phenotype information in
African Americans labeled as having H-ESRD is notoriously
poor, often a result of late referral to nephrologists and a
paucity of kidney biopsies. The difficulty classifying causes of
non-diabetic ESRD in African Americans, coupled with
strong familial aggregation, were reasons for initiating a
search for causative genetic factors. Regardless of the
underlying histology, which will never be available in these
696 subjects with H-ESRD, these association results demon-
strate that African Americans who are labeled with H-ESRD
by their treating nephrologists often have MYH9-associated
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kidney diseases. Evaluation of renal histology in those with
the early stages of MYH9-associated nephropathy will clarify
this issue.
There are many remaining questions in this rapidly
evolving story. Most importantly, are African Americans
with MYH9-associated renal disease responsive to immuno-
logic (or other) commonly applied therapies as prescribed for
FSGS? Should African-American subjects with non-nephrotic
proteinuria undergo renal biopsy, as well as testing for
MYH9? Should African Americans with newly diagnosed
hypertension undergo MYH9 testing and those found to be
homozygous for the risk haplotypes be treated to lower blood
pressure targets before the development of proteinuria?
Beyond HIV infection, what environmental factors trigger
progressive nephropathy in MYH9 risk homozygotes? Pro-
spective studies and clinical trials will be required to answer
these questions. We need to examine the role of MYH9 in
other kidney diseases disproportionately impacting African
Americans, such as lupus nephritis where affected individuals
often have relatives with non-lupus forms of kidney disease,
and the role of MYH9 gene polymorphism in kidney diseases
involving native African, Aboriginal and Afro-Caribbean
populations. The causative SNP and mechanism of action of
MYH9-associated kidney disease has not yet been fully
elucidated, although a new and exciting era has dawned with
this important discovery. MYH9 is the first major gene to be
identified using mapping by admixture disequilibrium. It is
also a gene with pronounced effect in common and complex
kidney disease.
In conclusion, MYH9 underlies a significant percentage of
non-diabetic etiologies of ESRD in African Americans,
particularly hypertension-associated ESRD. MYH9 is also
associated with disparate kidney diseases, such as HIVAN and
FSGS, which along with H-ESRD have been shown to
aggregate in single African-American families.3 The identifi-
cation of a gene expressed in podocytes and involved in the
motor regulation of cytoskeleton components, promises new
breakthroughs that may substantially reduce the burden of
ESRD in non-diabetic African Americans.
MATERIALS AND METHODS
Participants
Self-reported African Americans born in North Carolina, South
Carolina, Georgia, Virginia, or Tennessee formed the study
population. Peripheral blood specimens for DNA extraction were
collected from unrelated, prevalent hemodialysis, and peritoneal
dialysis patients in these states. Medical records were reviewed by a
single investigator (BIF). Subjects who had ESRD attributed to
H-ESRD, idiopathic, or secondary glomerular diseases on their CMS
2728 form were recruited. The majority of cases (696/871 or 79.9%)
were diagnosed as having H-ESRD by virtue of high blood pressure
preceding initiation of renal replacement therapy with hypertensive
target organ damage (retinopathy or left ventricular hypertrophy)
and low level proteinuria (p30 mg/100 ml on urine dipstick,o0.5 g
protein/24 h on timed urine collection, or urine protein/creatinine
ratio o0.5 g/g), or in the absence of proteinuria measurements
(review of dialysis records in 50 randomly selected H-ESRD cases
revealed that only 16% had quantitated urinary protein excretion).
In the presence of renal biopsy evidence of a primary glomerular
disease (for example, FSGS or membranous glomerulonephritis),
proteinuria X0.5 g/24 h or X100 mg/100 ml on urinalysis, non-
diabetic subjects were diagnosed as having chronic glomerular
disease-associated ESRD. Individuals with diabetic causes of ESRD
(type 1 or type 2) were excluded from these analyses, as were those
with renal cystic diseases, hereditary nephritis, or urologic causes of
ESRD. Diabetes-associated ESRD was diagnosed in patients with
either renal histologic evidence of diabetic nephropathy or with
diabetesX5 years before the initiation of renal replacement therapy
in the presence of diabetic retinopathy and/or proteinuria
4500 mg/24 h in the absence of other known causes of kidney
disease. Two hundred and forty one of the H-ESRD cases were
previously evaluated in the Kopp et al.11 report, demonstrating
association with the MYH9 E1 risk haplotype (P¼ 0.003 recessive
model, OR 1.8). These 241 individuals with H-ESRD (a subset of the
262 H-ESRD participant DNA samples submitted) were retained in
this analysis, and we included an additional 434 unrelated African
Americans with H-ESRD.
Unrelated, non-diabetic African Americans born in the same five
southeastern states served as controls. Control subjects denied a
personal or family history (in first degree relatives) of diabetes or
kidney disease (kidney disease was defined as kidney failure, dialysis,
or kidney transplantation); however, most did not have direct
measurement of renal function or blood pressure. Among the last
200 African American controls recruited, 0.5% (1/200) had a non-
fasting blood sugar 4150 mg/100 ml (value was 152 mg/100 ml) and
2% (4/200) had a serum creatinine concentration X1.5 mg per
100 ml (maximum¼ 1.85 mg/100 ml). The presence of occult kidney
disease in the control group would bias against association and
could deflate significance. The study was approved by the
Institutional Review Board at the Wake Forest University School
of Medicine and met criteria outlined in the Declaration of Helsinki
Principles. All participants provided written informed consent. DNA
from these participants was extracted using Puregene (Gentra,
Minneapolis, MN, USA).
SNP selection and genotyping
Fifteen SNPs in MYH9 were chosen for genotyping, based on those
previously selected by Kopp et al.11 for pronounced frequency
differences between reference Yoruban and European (CEU)
populations, possible functional significance, or strong LD with
SNPs typed in the original African American cohort with FSGS that
remained significantly associated after adjustment for admixture.
Tested SNPs included rs7078; rs12107; rs735853; rs5756129;
rs5756130; rs2187776; rs4821480; rs2032487; rs4821481;
rs3752462; rs5756152; rs1557539; rs1005570; rs16996674; and
rs16996677 (Figure 1). The MYH9 E1 risk haplotype containing
rs4821480, rs2032487, rs4821481, and rs3752462, previously asso-
ciated with FSGS and HIVAN, was evaluated.11 SNP genotyping was
performed on a Sequenom Mass Array Genotyping System
(Sequenom, San Diego, CA, USA).
Seventy di-allelic ancestry informative markers were genotyped
to determine whether population substructure biased our conclu-
sions. The African American cases and control DNA samples were
genotyped using either Illumina Inc’s Custom Genotyping Services
(San Diego, CA, USA) or using the Sequenom Mass Array
(San Diego). Thirty nine unrelated European American controls
were recruited, as described for the African American controls, and
DNA was obtained from 44 Yoruba Nigerians (YRI) from the
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National Institute of General Medicine Sciences (NIGMS) Human
Variation Collection (Coriell Repositories, Camden, NJ, USA).
Statistical analyses
Each SNP was tested for departures from Hardy–Weinberg
equilibrium expectations by a w2 goodness of fit test.29 LD was
estimated using the classic D0 and r2 statistics as implemented in
Dprime (http://www.phs.wfubmc.edu/public/bios/gene/downloads.
cfm) and Haploview 3.32.30 All tests of association are adjusted for
age, gender, and admixture proportions. The individual admixture
proportions were estimated by the expectation–maximization
algorithm implemented in the software FRAPPE.31 To test for an
association between each SNP and non-diabetic ESRD, we
computed the overall genotypic test of association and the three a
priori genetic models (dominant, additive, and recessive). We tested
for departures from additivity and computed the allelic and two-
and three-marker haplotypes. These tests were computed using
SNPGWA and Dandelion (http://www.phs.wfubmc.edu/public/bios/
gene/downloads.cfm); both programs use the expectation–maximi-
zation algorithm for haplotype estimation. Both the large sample test
distribution and permutation methods were used to estimate
statistical significance. As anticipated from the large-sample tests,
the most significant SNPs did not have a more extreme test statistic
in 10 million permutations of the data. The C-statistic was also
computed. For binary outcomes, the C-statistic is identical to the
area under the receiver–operating characteristic curve. It estimates
the probability of correctly identifying the case individual from a
randomly selected pair of individuals (1 case, 1 control) given the
genotype data and the estimated logistic regression model. The
C-statistic parameter varies between 0.5 (random prediction) and 1.0
(perfect prediction).
To examine the effect of SNPs outside the four marker E1
haplotypes, we estimated each person’s haplo–genotype probabilities
in Dandelion and computed a weighted logistic regression analysis.
Specifically, the logistic regression model contained age, gender,
admixture proportion, genetic model for the four marker haplo-
types (for example, dominant model for 3224 haplotype defined as
presence of the 3224 haplotype vs all other haplotypes), where the
weights are the corresponding haplo–genotype probabilities. Step-
wise methods (entry and exit criteria of 0.05) were used to examine
the independent contribution to risk of the individuals SNPs outside
the haplotype while adjusting for age, gender, admixture proportion,
and haplotype. In addition to the goal of testing for replication of
the haplotype previously reported, the independent contribution to
risk of all SNPs was of interest. Last, the stepwise logistic regression
analysis was repeated adjusting for age, gender, and admixture
proportion, without forcing the haplotype into the model.
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